This article was originally published in The Tan Sheet
Aventis' Allegra, Schering-Plough's Clarinex, Pfizer's Zyrtec likely will "be moved to a higher tier of co-payment in terms of...managed care formularies" with out-of-pocket costs "being in the range of $25 to $30" when Schering's Claritin switches OTC, Aventis Investor Relations Director Arvind Sood predicts during Q2 analysts call July 31. However, with a monthly supply of Claritin expected to cost about the same, the likelihood that Allegra customers will switch to Claritin "is going to be minimal," Sood maintains...
You may also be interested in...
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."